Co-Perineva^® (Tablets) Instructions for Use

ATC Code

C09BA04 (Perindopril and diuretics)

Active Substances

Indapamide (Rec.INN registered by WHO)

Perindopril (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Antihypertensive drug

Pharmacotherapeutic Group

Agents acting on the renin-angiotensin system; angiotensin-converting enzyme (ACE) inhibitors, combinations; ACE inhibitors and diuretics

Pharmacological Action

Antihypertensive combined drug.

Indapamide belongs to the group of sulfonamides and is pharmacologically close to thiazide diuretics. Indapamide inhibits the reabsorption of sodium ions in the cortical segment of the loop of Henle, which leads to an increased renal excretion of sodium and chloride ions and, to a lesser extent, potassium and magnesium ions, thereby enhancing diuresis and reducing blood pressure.

The antihypertensive effect is manifested when the drug is used in doses that have a minimal diuretic effect.

The antihypertensive effect of indapamide is associated with an improvement in the elastic properties of large arteries and a decrease in total peripheral vascular resistance.

Perindopril is an ACE inhibitor. ACE, or kininase II, is an exopeptidase that carries out both the conversion of angiotensin I to the vasoconstrictor substance angiotensin II and the degradation of bradykinin, which has a vasodilatory effect, to an inactive heptapeptide.

As a result, perindopril reduces the secretion of aldosterone; by the principle of negative feedback, it increases plasma renin activity; with long-term use, it reduces total peripheral vascular resistance, which is mainly due to its effect on blood vessels in muscles and kidneys. These effects are not accompanied by sodium and fluid retention or the development of reflex tachycardia.

Perindopril normalizes myocardial function, reducing preload and afterload.

In studies of hemodynamic parameters in patients with chronic heart failure (CHF), the following were revealed: a decrease in filling pressure in the left and right ventricles of the heart; a decrease in total peripheral vascular resistance; an increase in cardiac output; enhanced muscular peripheral blood flow.

Perindopril is effective for the treatment of arterial hypertension of any severity.

The antihypertensive effect reaches its maximum 4-6 hours after a single oral dose and persists for 24 hours. 24 hours after administration, a pronounced residual inhibition of ACE (about 80%) is observed.

Perindopril exerts an antihypertensive effect in patients with both low and normal plasma renin activity.

Concomitant use of thiazide diuretics enhances the severity of the antihypertensive effect. In addition, the combination of an ACE inhibitor and a thiazide diuretic also leads to a reduction in the risk of hypokalemia during diuretic therapy.

The combined drug has a dose-dependent antihypertensive effect on both diastolic and systolic blood pressure, in both the standing and lying positions. It reduces left ventricular hypertrophy, does not affect plasma lipid concentrations (triglycerides, total cholesterol, LDL, HDL), carbohydrate metabolism (including in patients with concomitant diabetes mellitus). The antihypertensive effect persists for 24 hours. A stable therapeutic effect develops in less than 1 month from the start of therapy and is not accompanied by tachyphylaxis. Discontinuation of treatment does not cause a withdrawal syndrome.

Pharmacokinetics

The combination of indapamide and perindopril does not change their pharmacokinetic characteristics compared to the separate administration of these drugs.

Indapamide is rapidly and completely absorbed from the gastrointestinal tract. The C_max of the drug in plasma is observed 1 hour after oral administration. Plasma protein binding is 79%. The T_1/2 is 14-24 hours (average 19 hours). Repeated administration of the drug does not lead to its accumulation in the body. It is excreted mainly by the kidneys (70% of the administered dose) and through the intestines (22%) in the form of inactive metabolites.

When taken orally, perindopril is rapidly absorbed. Bioavailability is 65-70%. Approximately 20% of the total amount of absorbed perindopril is converted to perindoprilat, the active metabolite. Taking the drug with food is accompanied by a reduction in the metabolism of perindopril to perindoprilat (this effect has no significant clinical importance). C_max of perindoprilat in plasma is reached 3-4 hours after oral administration. Plasma protein binding is less than 30% and depends on the concentration of perindopril in plasma. The dissociation of perindoprilat bound to ACE is slowed. Consequently, the effective T_1/2 is 25 hours. Repeated administration of perindopril does not lead to its accumulation, and the T_1/2 of perindoprilat upon repeated administration corresponds to its period of activity, thus, a steady state is reached after 4 days. Perindopril crosses the placental barrier. Perindoprilat is excreted from the body by the kidneys. The T_1/2 of the metabolite is 3-5 hours. The elimination of perindoprilat is slowed in the elderly, as well as in patients with heart and renal failure. The dialysis clearance of perindoprilat is 70 ml/min. The pharmacokinetics of perindopril are altered in patients with liver cirrhosis: its hepatic clearance is reduced by half. Nevertheless, the amount of perindoprilat formed does not decrease, so no dose adjustment is required.

Indications

Essential arterial hypertension.

ICD codes

Dosage Regimen

Tablets

For oral administration. A single dose is taken once a day.

For patients with moderate renal impairment (creatinine clearance 30-60 ml/min), it is recommended to start therapy with the necessary doses of single-component drugs. The maximum recommended dose of the perindopril/Indapamide combination is 0.625 mg/2 mg once a day.

For patients with creatinine clearance equal to or greater than 60 ml/min, no dose adjustment is required, provided that plasma creatinine and potassium levels are regularly monitored.

Adverse Reactions

Perindopril has an inhibitory effect on the RAAS and reduces the renal excretion of potassium ions during indapamide administration.

From the hematopoietic system very rarely – thrombocytopenia, leukopenia/neutropenia, agranulocytosis, aplastic anemia, hemolytic anemia.

From the nervous system often – paresthesia, headache, dizziness, asthenia, vertigo; infrequently – sleep disorder, mood lability; very rarely – confusion; frequency unknown – syncope.

From the organ of vision often – visual impairment.

From the organ of hearing often – tinnitus.

From the cardiovascular system often – marked decrease in blood pressure, including orthostatic hypotension; very rarely – cardiac arrhythmias, including bradycardia, ventricular tachycardia, atrial fibrillation, as well as angina pectoris and myocardial infarction, possibly due to excessive blood pressure reduction in high-risk patients; frequency unknown – polymorphic ventricular tachycardia of the “torsades de pointes” type (possibly fatal).

From the respiratory system often – during the use of ACE inhibitors, a dry cough may occur (persisting for a long time during treatment with drugs of this group and disappearing after their discontinuation), dyspnea; infrequently – bronchospasm; very rarely – eosinophilic pneumonia, rhinitis.

From the digestive system often – dry mouth, nausea, vomiting, abdominal pain, epigastric pain, taste disturbance, decreased appetite, dyspepsia, constipation, diarrhea; very rarely – intestinal angioedema, cholestatic jaundice, pancreatitis, cytolytic or cholestatic hepatitis; frequency unknown – hepatic encephalopathy in patients with hepatic insufficiency.

From the skin and subcutaneous tissues often – skin rash, pruritus, maculopapular rash; infrequently – angioedema of the face, lips, extremities, tongue mucosa, vocal folds and/or larynx, urticaria, hypersensitivity reactions in patients predisposed to bronchospastic and allergic reactions, purpura; in patients with acute systemic lupus erythematosus, a worsening of the disease course is possible; very rarely – erythema multiforme, toxic epidermal necrolysis, Stevens-Johnson syndrome; cases of photosensitivity reactions have been noted.

From the musculoskeletal system and connective tissue often – muscle cramps.

From the urinary system infrequently – renal failure; very rarely – acute renal failure.

From the reproductive system infrequently – impotence.

General reactions often – asthenia; infrequently – increased sweating.

Laboratory parameters rarely – hypercalcemia; frequency unknown – QT interval prolongation on ECG; increased plasma uric acid and glucose levels; increased activity of liver enzymes; hypokalemia, especially significant for patients at risk; hyponatremia and hypovolemia, leading to dehydration and orthostatic hypotension. Simultaneous hypochloremia can lead to compensatory metabolic alkalosis (the likelihood and severity of this effect is low); hyperkalemia, often transient; a slight increase in the concentration of creatinine in urine and plasma, which resolves after discontinuation of therapy, more often in patients with renal artery stenosis, during the treatment of arterial hypertension with diuretics and in case of renal failure.

Contraindications

History of angioedema (including while taking other ACE inhibitors); hereditary/idiopathic angioedema; severe renal failure (creatinine clearance less than 30 ml/min); bilateral renal artery stenosis or presence of a single functioning kidney; hepatic encephalopathy; severe hepatic insufficiency; hypokalemia; concomitant use of drugs that prolong the QT interval; concomitant use of drugs that can cause polymorphic ventricular tachycardia of the “torsades de pointes” type; concomitant use with drugs containing aliskiren in patients with diabetes mellitus or renal impairment (GFR less than 60 ml/min/1.73 m²); pregnancy; lactation period (breastfeeding); age under 18 years; hypersensitivity to perindopril or other ACE inhibitors, indapamide and other sulfonamide derivatives.

Due to insufficient clinical experience, this combination should not be used: in patients on hemodialysis; in patients with untreated decompensated heart failure.

With caution

Aortic valve stenosis/hypertrophic obstructive cardiomyopathy; renovascular hypertension, hyponatremia (increased risk of arterial hypotension in patients who are on a salt-free diet or a diet with reduced sodium content); hypovolemia (including diarrhea, vomiting); systemic connective tissue diseases (including systemic lupus erythematosus, scleroderma); therapy with immunosuppressants (risk of neutropenia, agranulocytosis); diabetes mellitus, gout, bone marrow depression, hyperuricemia (especially accompanied by gout and urate nephrolithiasis), hyperkalemia, angina pectoris, cerebrovascular diseases (including cerebral circulatory insufficiency), chronic heart failure (NYHA functional class IV), hepatic insufficiency, old age, labile blood pressure, representatives of the black race (reduced efficacy), athletes (possible positive reaction in doping control), hemodialysis using high-flux membranes or desensitization before LDL apheresis procedure, status after kidney transplantation, therapy with lithium preparations, anesthesia.

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy and during the lactation period (breastfeeding).

Use in Hepatic Impairment

In severe liver dysfunction, treatment with this drug is contraindicated.

In moderate hepatic insufficiency, no dose adjustment is required.

Use in Renal Impairment

In severe renal failure (creatinine clearance less than 30 ml/min), treatment with the drug Perindopril-Indapamide Richter is contraindicated. In moderate renal failure (creatinine clearance 30-60 ml/min), it is recommended to start therapy with the combined drug depending on blood pressure. For patients with creatinine clearance greater than 60 ml/min, no dose adjustment is required with regular monitoring of creatinine and potassium levels.

Pediatric Use

The drug is contraindicated for use in children and adolescents under 18 years of age.

Geriatric Use

Treatment in elderly patients should be initiated taking into account the reduction in blood pressure and renal function.

Special Precautions

In some patients with arterial hypertension without prior obvious renal impairment, laboratory signs of functional renal failure may appear during therapy. In this case, treatment should be discontinued. When resuming combination therapy, the components should be used in low doses or only one of them should be used. Such patients require regular monitoring of serum potassium and creatinine levels – 2 weeks after the start of therapy and every 2 months thereafter. Renal failure occurs more often in patients with severe chronic heart failure or pre-existing renal impairment, including renal artery stenosis.

In case of pre-existing hyponatremia, there is a risk of sudden development of arterial hypotension, especially in patients with renal artery stenosis. Therefore, during dynamic observation of patients, attention should be paid to possible symptoms of dehydration and decreased plasma electrolyte levels, for example, after diarrhea or vomiting. Such patients require regular monitoring of plasma electrolyte levels.

The combined use of perindopril and indapamide does not prevent the development of hypokalemia, especially in patients with diabetes mellitus or renal failure. As with the combination of any antihypertensive drug and a diuretic, regular monitoring of plasma potassium levels is necessary.

Concomitant administration of perindopril and potassium-sparing diuretics, as well as potassium preparations, potassium-containing salt substitutes and dietary supplements is not recommended.

In patients with normal renal function and no concomitant risk factors, neutropenia occurs rarely. Perindopril should be used with particular caution in the context of systemic connective tissue diseases (including systemic lupus erythematosus, scleroderma), as well as during treatment with immunosuppressants, allopurinol or procainamide, or a combination of these factors, especially in patients with pre-existing impaired renal function. Some of these patients developed severe infections, in some cases resistant to intensive antibiotic therapy. When prescribing perindopril to such patients, it is recommended to periodically monitor the white blood cell count. Patients should report any signs of infectious diseases (e.g., sore throat, fever) to their doctor.

When taking ACE inhibitors, including perindopril, in rare cases, the development of angioedema of the face, extremities, lips, tongue, vocal folds and/or larynx may be observed. This can occur at any time during treatment. If symptoms appear, the drug should be discontinued immediately, and the patient should be observed until the signs of edema completely disappear. If the edema involves only the face and lips, it usually resolves on its own, although antihistamines may be used as symptomatic therapy. Angioedema accompanied by laryngeal edema can be fatal. Swelling of the tongue, vocal folds, or larynx can lead to airway obstruction. If such symptoms appear, appropriate therapy should be started immediately, for example, subcutaneous administration of epinephrine (adrenaline) in a 1:1000 dilution (0.3-0.5 ml) and/or ensuring airway patency.

A higher risk of developing angioedema has been reported in black patients.

Patients with a history of angioedema not associated with ACE inhibitor use may have an increased risk of its development when taking drugs of this group.

In patients with abdominal pain receiving ACE inhibitors, the possibility of intestinal angioedema should be considered in the differential diagnosis.

There are isolated reports of the development of prolonged, life-threatening anaphylactoid reactions in patients receiving ACE inhibitors during desensitizing therapy with hymenoptera venom (bees, wasps). ACE inhibitors should be used with caution in allergy-prone patients undergoing desensitization procedures. The prescription of an ACE inhibitor should be avoided in patients receiving immunotherapy with hymenoptera venom. However, an anaphylactoid reaction can be avoided by temporarily discontinuing

In rare cases, in patients receiving ACE inhibitors, life-threatening anaphylactoid reactions developed during LDL apheresis using dextran sulfate. To prevent an anaphylactoid reaction, therapy with the ACE inhibitor should be temporarily discontinued before each apheresis procedure.

In patients receiving ACE inhibitors, anaphylactoid reactions have been observed during hemodialysis using high-flux membranes (e.g., AN69^®). Therefore, it is advisable to use a different type of membrane or use an antihypertensive agent of a different pharmacotherapeutic group.

In some pathological conditions, significant activation of the RAAS may be noted, especially in cases of marked hypovolemia and decreased plasma electrolyte levels (against the background of a salt-free diet or long-term diuretic use), in patients with initially low blood pressure, renal artery stenosis, chronic heart failure, or liver cirrhosis with edema and ascites. The use of an ACE inhibitor causes blockade of this system and therefore may be accompanied by a sharp decrease in blood pressure and/or an increase in plasma creatinine concentration, indicating the development of functional renal failure. These phenomena are more often observed when taking the first dose of the drug or during the first two weeks of therapy. Sometimes these conditions develop acutely at other times of therapy. In such cases, when resuming therapy, it is recommended to use the drug at a lower dose and then gradually increase it.

Before starting the medication, it is necessary to assess renal functional activity and plasma potassium levels. At the beginning of therapy, the dose is selected considering the degree of blood pressure reduction, especially in cases of dehydration and electrolyte loss. These measures help to avoid a sharp decrease in blood pressure.

The risk of arterial hypotension exists for all patients; however, special caution should be exercised when using the drug in patients with coronary artery disease and cerebrovascular insufficiency. In such patients, treatment should be started with low doses.

Treatment with the perindopril/Indapamide combination in patients with diagnosed or suspected renal artery stenosis should be initiated with a low dose of the drug in a hospital setting, monitoring renal function and plasma potassium levels. Some patients may develop functional renal insufficiency, which resolves upon discontinuation of this combination.

In individuals with severe heart failure (NYHA functional class IV) and patients with type 1 diabetes mellitus (risk of spontaneous increase in potassium levels), treatment should be started with a low dose of the drug and under careful medical supervision.

During the first month of therapy with ACE inhibitors, plasma glucose concentration should be carefully monitored in patients with diabetes mellitus receiving treatment with oral hypoglycemic agents or insulin.

Perindopril, like other ACE inhibitors, apparently has a less pronounced antihypertensive effect in patients of Black race compared to representatives of other races. This difference is possibly due to the fact that hypertensive patients of Black race more frequently have low renin activity.

Performing general anesthesia while using ACE inhibitors can lead to a pronounced decrease in blood pressure, especially when using general anesthetic agents with hypotensive action. It is recommended to discontinue long-acting ACE inhibitors, including perindopril, if possible, one day before surgery. The anesthesiologist must be informed that the patient is taking ACE inhibitors.

If jaundice or a significant increase in liver enzyme activity occurs during treatment with ACE inhibitors, the drug should be discontinued and a doctor should be consulted.

Hyperkalemia may develop during treatment with ACE inhibitors, including perindopril. Hyperkalemia can lead to serious, sometimes fatal, cardiac arrhythmias. Risk factors for hyperkalemia are renal failure, worsening renal function, age over 70 years, diabetes mellitus, certain concomitant conditions (dehydration, acute decompensation of heart failure, metabolic acidosis), concurrent use of potassium-sparing diuretics (such as spironolactone and its derivative eplerenone, triamterene, amiloride), as well as a number of other medicinal products. In such cases, treatment should be conducted with caution under regular monitoring of serum potassium levels.

Before starting treatment, the plasma sodium ion level should be determined. During drug administration, this indicator should be monitored regularly. All diuretic drugs can cause hyponatremia, which sometimes leads to serious complications. Hyponatremia at the initial stage may not be accompanied by clinical symptoms, so regular laboratory monitoring is necessary. More frequent monitoring of sodium ion levels is indicated for patients with liver cirrhosis and elderly patients.

Therapy with thiazide and thiazide-like diuretics is associated with the risk of developing hypokalemia. Hypokalemia (less than 3.4 mmol/L) must be avoided in the following high-risk patient categories: elderly patients, debilitated patients (both receiving and not receiving concomitant drug therapy), patients with liver cirrhosis (with edema and ascites), coronary artery disease, heart failure. Hypokalemia in these patients enhances the toxic effect of cardiac glycosides and increases the risk of arrhythmias.

The high-risk group also includes patients with a prolonged QT interval, both congenital and drug-induced.

Hypokalemia, like bradycardia, contributes to the development of severe cardiac arrhythmias, particularly polymorphic ventricular tachycardia of the “torsades de pointes” type, which can be fatal. In all the cases described above, more regular monitoring of plasma potassium ion levels is necessary. The first measurement of potassium ion levels should be performed within the first week of starting therapy. If hypokalemia is detected, appropriate treatment should be prescribed.

Thiazide and thiazide-like diuretics can reduce the renal excretion of calcium ions, leading to a slight and temporary increase in plasma calcium concentration. Marked hypercalcemia may be a consequence of previously undiagnosed hyperparathyroidism. Diuretic agents should be discontinued before testing parathyroid function.

Blood glucose concentration should be monitored in patients with diabetes mellitus, especially in the presence of hypokalemia.

If the concentration of uric acid in the blood plasma increases during therapy, the frequency of gout attacks may increase.

Thiazide and thiazide-like diuretics are fully effective only in patients with normal or slightly impaired renal function (plasma creatinine concentration in adults below 25 mg/L or 220 µmol/L).

At the beginning of diuretic treatment, patients may experience a temporary decrease in GFR and an increase in plasma urea and creatinine levels due to hypovolemia and hyponatremia. This transient functional renal insufficiency is not dangerous for patients with initially normal renal function, but its severity may increase in patients with renal insufficiency.

Indapamide may yield a positive reaction during doping control.

Effect on the Ability to Drive Vehicles and Operate Machinery

The action of indapamide and perindopril, both individually and in combination, does not lead to impairment of psychomotor reactions. However, some individuals may develop various individual reactions in response to decreased blood pressure, especially at the beginning of treatment or when other antihypertensive drugs are added to the therapy. In this case, the ability to drive a car or operate machinery may be reduced.

Drug Interactions

Lithium preparations: concurrent use of lithium preparations and ACE inhibitors may cause a reversible increase in plasma lithium concentration and related toxic effects. Additional prescription of thiazide diuretics may contribute to a further increase in lithium concentration and increase the risk of toxicity manifestations. Concurrent use of the perindopril and indapamide combination with lithium preparations is not recommended. If such therapy is necessary, plasma lithium levels should be monitored regularly.

Baclofen: enhancement of the antihypertensive effect is possible. Blood pressure and renal function should be monitored; adjustment of the dose of antihypertensive drugs may be required.

NSAIDs, including high doses of acetylsalicylic acid (≥ 3 g/day): concurrent use of ACE inhibitors with NSAIDs (acetylsalicylic acid at a dose exerting an anti-inflammatory effect, COX-2 inhibitors, and non-selective NSAIDs) may lead to a reduction of the antihypertensive effect.

Concurrent use of ACE inhibitors and NSAIDs may lead to an increased risk of worsening renal function, including the development of acute renal failure, and an increase in serum potassium levels, especially in patients with pre-existing reduced renal function. Caution should be exercised when prescribing this combination and NSAIDs, especially in elderly patients: patients should receive adequate fluids, and it is recommended to monitor renal function both at the start of combination therapy and periodically during treatment.

Tricyclic antidepressants, antipsychotic agents (neuroleptics): drugs of these classes enhance the antihypertensive effect and increase the risk of orthostatic hypotension (additive effect).

Corticosteroids, tetracosactide: reduction of the antihypertensive effect (fluid and sodium ion retention as a result of corticosteroid action).

Other antihypertensive agents: enhancement of the antihypertensive effect is possible.

Clinical trial data indicate that dual blockade of the RAAS resulting from concurrent use of ACE inhibitors, ARBs, or aliskiren leads to an increased frequency of adverse events such as arterial hypotension, hyperkalemia, and renal function impairments (including acute renal failure), compared to situations where only one drug affecting the RAAS is used.

ACE inhibitors can cause angioedema. The risk of angioedema may increase with concurrent use of racecadotril (used for acute diarrhea).

Mammalian target of rapamycin (mTOR) inhibitors (sirolimus, everolimus, temsirolimus). The risk of developing angioedema is increased in patients taking mTOR inhibitors concurrently with ACE inhibitors.

Potassium-sparing diuretics (amiloride, spironolactone, triamterene) and potassium preparations: ACE inhibitors reduce potassium loss caused by the diuretic. Potassium-sparing diuretics (e.g., spironolactone, eplerenone, triamterene, amiloride), potassium preparations, and potassium-containing salt substitutes can lead to a significant increase in serum potassium levels, even to a fatal outcome. If concurrent use of an ACE inhibitor and the aforementioned drugs is necessary (in case of confirmed hypokalemia), caution should be exercised, and regular monitoring of plasma potassium levels and ECG parameters should be conducted.

Estramustine: concurrent use may lead to an increased risk of side effects, such as angioedema.

Oral hypoglycemic agents (sulfonylurea derivatives) and insulin: the effects described below have been reported for captopril and enalapril. ACE inhibitors may enhance the hypoglycemic effect of insulin and sulfonylurea derivatives in patients with diabetes mellitus. The development of hypoglycemia is observed very rarely (due to increased glucose tolerance and reduced insulin requirement).

Antihypertensive agents and vasodilators: concurrent use of these drugs may enhance the antihypertensive effect of perindopril. When used concurrently with nitroglycerin, other nitrates, or other vasodilators, an additional decrease in blood pressure is possible.

Allopurinol, cytotoxic and immunosuppressive agents, corticosteroids (for systemic use), and procainamide: concurrent use with ACE inhibitors may be associated with an increased risk of leukopenia.

General anesthetic agents: concurrent use of ACE inhibitors and general anesthetic agents may lead to an enhancement of the antihypertensive effect.

Diuretics (thiazide and “loop”): use of diuretics in high doses can lead to hypovolemia, and the addition of perindopril to therapy can lead to arterial hypotension.

Gliptins (linagliptin, saxagliptin, sitagliptin, vildagliptin): when used concurrently with ACE inhibitors, the risk of angioedema increases due to inhibition of dipeptidyl peptidase-4 (DPP-IV) activity by the gliptin.

Sympathomimetics: may weaken the antihypertensive effect of ACE inhibitors.

Gold preparations: in patients taking ACE inhibitors, including perindopril, and receiving intravenous gold preparation (sodium aurothiomalate), nitrate-like reactions have been described, including: facial flushing, nausea, vomiting, arterial hypotension.

Drugs that can cause polymorphic ventricular tachycardia of the “torsades de pointes” type due to the risk of developing hypokalemia, caution should be exercised when using indapamide concurrently with drugs that can cause polymorphic ventricular tachycardia of the “torsades de pointes” type, for example, class IA antiarrhythmic agents (quinidine, hydroquinidine, disopyramide) and class III (amiodarone, dofetilide, ibutilide, bretylium tosylate), sotalol; some neuroleptics (chlorpromazine, cyamemazine, levomepromazine, thioridazine, trifluoperazine); benzamides (amisulpride, sulpiride, sultopride, tiapride); butyrophenones (droperidol, haloperidol); other neuroleptics (pimozide); other drugs such as bepridil, cisapride, difemanil methyl sulfate, intravenous erythromycin, halofantrine, mizolastine, moxifloxacin, pentamidine, sparfloxacin, intravenous vincamine, methadone, astemizole, terfenadine. Plasma potassium levels should be monitored and corrected if necessary; the QT interval should be monitored.

Drugs that can cause hypokalemia: amphotericin B (IV), gluco- and mineralocorticoids (for systemic use), tetracosactide, stimulant laxatives: increased risk of developing hypokalemia (additive effect). Monitoring of plasma potassium levels is necessary, with correction if needed. Particular attention should be paid to patients concurrently receiving cardiac glycosides. Non-stimulant laxatives should be used.

Cardiac glycosides: hypokalemia enhances the toxic effect of cardiac glycosides. When using indapamide and cardiac glycosides concurrently, plasma potassium levels and ECG parameters should be monitored, and therapy should be adjusted if necessary.

Metformin: functional renal insufficiency, which can occur during diuretic use, especially “loop” diuretics, when prescribed concurrently with metformin increases the risk of lactic acidosis. Metformin should not be used if plasma creatinine concentration exceeds 15 mg/L (135 µmol/L) in men and 12 mg/L (110 µmol/L) in women.

Iodinated contrast agents: dehydration of the body during diuretic use increases the risk of acute renal failure, especially when using high doses of iodinated contrast agents. Before using iodinated contrast agents, patients must compensate for fluid loss.

Calcium salts: when prescribed concurrently, hypercalcemia may develop due to reduced renal excretion of calcium ions.

Cyclosporine: an increase in plasma creatinine concentration may occur without changes in plasma cyclosporine concentration, even with normal water and sodium ion levels.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.